Chapter-09 Anogenital Warts

2013 ◽  
pp. 85-96
Author(s):  
Neena Khanna
Keyword(s):  
Anogenital Warts

A Never-Ending Story of Anogenital Warts: Review Article

2020 ◽  
Vol 103 (6) ◽  
pp. 614-619
Keyword(s):  
Hpv Vaccine ◽  
Social Issues ◽  
Anogenital Warts ◽  
Negative Effects ◽  
Fatal Disease ◽  
Anogenital Wart ◽  
Sexually Transmitted ◽  
Dormant Stage ◽  
Ideal Method ◽  
Basic Medical

Anogenital wart (AGW) has long been one of the most common sexually transmitted infections, which has negative effects on psychological and social issues. Its slowly progressive nature and long dormant stage prevent AGW from elimination. Although diagnosis is as simple as inspection using the naked eyes or a magnifying glass and basic medical treatment is the main treatment modality, the long period of clinical response appears to be the biggest challenge. Many patients suffer from this non-fatal disease for over half a year. Onward transmission obviously continues during the occurrence of lesions. Primary prevention, particularly vaccination against human papillomavirus (HPV vaccine), is an ideal method. HPV vaccine is a promising method; however, its high cost limits wide accessibility. In addition, despite being vaccinated, some women present with AGW. Therefore, a never-ending story of AGW remains to be explored. The Siriraj Female STI Clinic, which has over 20 years of experience in treating women with AGW, would like to share some experience so that these patients will be treated with more understanding. Keywords: Anogenital wart, Prevention, Surveillance, Siriraj experience

Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts

2008 ◽  
Vol 19 (7) ◽  
pp. 441-444 ◽  
Author(s):  
Christina Stefanaki ◽  
Ilias Katzouranis ◽  
Eirini Lagogianni ◽  
Maria Hagjivassiliou ◽  
Electra Nicolaidou ◽  
...  
Keyword(s):  
Anogenital Warts

Anogenital Warts Knowledge and Counseling Practices of US Clinicians: Results From a National Survey

2007 ◽  
Vol 34 (9) ◽  
pp. 644-652 ◽  
Author(s):  
Zsakeba Henderson ◽  
Kathleen L. Irwin ◽  
Daniel E. Monta??o ◽  
Danuta Kasprzyk ◽  
Linda Carlin ◽  
...  
Keyword(s):  
National Survey ◽  
Anogenital Warts ◽  
Counseling Practices

scholarly journals Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates

2018 ◽  
Vol 95 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Koh Jun Ong ◽  
Marta Checchi ◽  
Lorna Burns ◽  
Charlotte Pavitt ◽  
Maarten J Postma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Anal Cancer ◽  
Penile Cancer ◽  
Vulvar Cancer ◽  
Head And Neck Cancers ◽  
Economic Evaluations ◽  
Anogenital Warts ◽  
Utility Elicitation

BackgroundMany economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.MethodsWe conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider’s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$.ResultsSixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124–US$883 (anogenital warts), US$6912–US$52 579 (head and neck cancers), US$12 936–US$51 571 (anal cancer), US$17 524–34 258 (vaginal cancer), US$14 686–US$28 502 (vulvar cancer) and US$9975–US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).ConclusionsDifferences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

Sign in / Sign up

Export Citation Format

Share Document